Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process requires cooperation from industry, academic researchers, advocacy groups, and patients as well as their caregivers and families. In this white paper, we look at the barriers drug developers face when positioning a new trial in the rare disease space and how to minimize these barriers by applying a multi-stakeholder collaborative approach to drug development.
You may also be interested in:
White Paper
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…
Case Study
Creating Solutions to Ensure Endpoint Protection in Challenging Rare Disease Trial
The collection of high-quality endpoint data was paramount to the success of this Phase II program. Because this was the first clinical trial ever…
Page
Clinical Research Associate
PRA Clinical Research Associates (CRAs) choose one of two career paths. They may work onsite with one of our top pharmaceutical clients. Or they may…